Sonara Health is excited to announce that we have successfully raised $4,700,000—a significant milestone in our journey to revolutionize opioid treatment programs (OTP). This new funding will accelerate our mission to support OTP patients with more accessible, reliable, and remote dosing solutions. Sonara® is pioneering the Virtual Dosing Window™, a patented technology that empowers patients in methadone treatment programs by enabling them to record their take-home doses using a simple phone or computer. Through scanning the QR code on their methadone bottles and recording a video of the dosing process, patients can securely share real-time insights with their care teams. In turn, these insights help clinicians make informed decisions and build trust, which not only enhances treatment outcomes but also increases the likelihood of earning additional take-home doses. With this infusion of capital, we plan to further develop and deploy our innovative solution, expand our market reach, and support additional research efforts that underscore the value of remote care in the management of opioid use disorder.
The funds will also be instrumental in building strategic partnerships, refining our technology, and scaling our operations to serve OTPs across more diverse geographical regions, including those with patients living far from the centralized clinics. Backed by respected investors such as Mark Cuban and First Trust Capital, our commitment to delivering accessible and effective treatment alternatives stands stronger than ever. With Sonara, patients are given the opportunity to pursue recovery and reclaim their lives without unnecessary disruptions, reaffirming that treatment accessibility and quality go hand in hand. We look forward to partnering with clinics and healthcare providers to drive a transformative impact in the world of opioid recovery.
